Advertisement

Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990–2001)

Gabriella SfiligoiDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.
Present address is Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Gabriella Sfiligoi in
Current site
Google Scholar
PubMed
Close
 DVM
,
Kenneth M. RassnickDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Kenneth M. Rassnick in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Janet M. ScarlettDepartment of Population Medicine and Diagnostic Science, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Janet M. Scarlett in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Nicole C. NorthrupComparative Oncology Program, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Nicole C. Northrup in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
, and
Tracy L. GiegerDepartment of Surgery and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA 95616.
Present address is Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.

Search for other papers by Tracy L. Gieger in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM

Abstract

Objective—To compare clinical outcome of dogs with cutaneous mast cell tumors (MCTs) in the inguinal or perineal region with outcome for dogs with MCTs in other cutaneous locations.

Design—Retrospective study.

Animals—37 dogs with MCTs in the inguinal or perineal region and 87 dogs with MCTs in other cutaneous locations.

Procedure—Information obtained from the medical records included sex, breed, age, histologic grade of all tumors, number and location of all tumors, tumor size (ie, diameter of the tumor), completeness of surgical excision, treatments administered in addition to surgery, and outcome. In all dogs, the primary treatment consisted of surgical excision.

Results—Disease-free interval and survival time for dogs with MCTs in the inguinal or perineal region were not significantly different from values for dogs with MCTs in other cutaneous locations. Dogs with incompletely excised tumors, dogs with grade III tumors, and dogs that received systemic treatment were 2, 2.5, and 4 times as likely, respectively, to have a relapse. Factors significantly associated with a shorter survival time were age > 8 years, metastatic disease at the time of initial diagnosis, and tumor relapse.

Conclusions and Clinical Relevance—Results of the present study suggest that dogs with MCTs in the inguinal or perineal region do not have a worse prognosis in regard to disease-free interval or survival time than do dogs with MCTs in other cutaneous locations. Treatment recommendations for dogs with cutaneous MCTs should be based on confirmed predictors of biological behavior, such as histologic grade and clinical stage. (J Am Vet Med Assoc 2005;226:1368–1374)

Abstract

Objective—To compare clinical outcome of dogs with cutaneous mast cell tumors (MCTs) in the inguinal or perineal region with outcome for dogs with MCTs in other cutaneous locations.

Design—Retrospective study.

Animals—37 dogs with MCTs in the inguinal or perineal region and 87 dogs with MCTs in other cutaneous locations.

Procedure—Information obtained from the medical records included sex, breed, age, histologic grade of all tumors, number and location of all tumors, tumor size (ie, diameter of the tumor), completeness of surgical excision, treatments administered in addition to surgery, and outcome. In all dogs, the primary treatment consisted of surgical excision.

Results—Disease-free interval and survival time for dogs with MCTs in the inguinal or perineal region were not significantly different from values for dogs with MCTs in other cutaneous locations. Dogs with incompletely excised tumors, dogs with grade III tumors, and dogs that received systemic treatment were 2, 2.5, and 4 times as likely, respectively, to have a relapse. Factors significantly associated with a shorter survival time were age > 8 years, metastatic disease at the time of initial diagnosis, and tumor relapse.

Conclusions and Clinical Relevance—Results of the present study suggest that dogs with MCTs in the inguinal or perineal region do not have a worse prognosis in regard to disease-free interval or survival time than do dogs with MCTs in other cutaneous locations. Treatment recommendations for dogs with cutaneous MCTs should be based on confirmed predictors of biological behavior, such as histologic grade and clinical stage. (J Am Vet Med Assoc 2005;226:1368–1374)